TCA
TCRX icon

Troluce Capital Advisors’s TScan Therapeutics TCRX Stock Holding History

Troluce Capital Advisors’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-150,000
Closed -$218K – 49
2025
Q2 		$218K Buy
150,000
+66,242
+79% +$95.7K 0.05% 30
2025
Q1 		$116K Buy
83,758
+30,844
+58% +$66.7K 0.03% 31
2024
Q4 		$161K Hold
52,914
– – 0.01% 33
2024
Q3 		$264K Sell
52,914
-39,918
-43% -$241K 0.02% 80
2024
Q2 		$543K Buy
+92,832
New +$731K 0.05% 70

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Troluce Capital Advisors's TCRX Position: Q3 2025 in Review

Troluce Capital Advisors sold out of TScan Therapeutics (TCRX) in Q3 2025, closing a stake of 150,000 shares — an estimated $218K sold.

Troluce Capital Advisors first reported a position in TCRX in Q2 2024 and held it in 5 quarters. The position peaked at $543K in Q2 2024. 73 funds tracked by Wall St. Rank hold TCRX as of Q3 2025.

  • Troluce Capital Advisors reported no remaining TScan Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Troluce Capital Advisors sold 150,000 TScan Therapeutics shares in Q3 2025, an estimated $218K.
  • Troluce Capital Advisors first reported a position in TScan Therapeutics in Q2 2024 and held it in 5 quarters.
  • Troluce Capital Advisors's TScan Therapeutics position peaked at $543K in Q2 2024.
  • 73 funds tracked by Wall St. Rank held TScan Therapeutics as of Q3 2025.

Based on Troluce Capital Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.